Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Inks Deal to Distribute Grifols Immunohematology Products

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Spanish healthcare and biopharmaceutical manufacturing firm Grifols today announced a deal with Novartis Diagnostics to commercialize certain Grifols products in the US.

Following regulatory approval in the US, the Novartis business would market and distribute Grifols' immunohematology instruments, assays, and other products, under the terms of the deal. Novartis will also market and distribute semi-automated, pre-transfusion diagnostic products made by subsidiaries of Grifols and Progenika blood group antigen genotyping products that are currently distributed by Grifols.

During the summer, Grifols and Progenika partnered on a distribution deal covering Progenika's microchip blood typing technology called Bloodchip.

Financial and other terms of today's agreement were not disclosed.

In a statement, Grifols, based in Barcelona, Spain, said that Novartis will help strengthen its position in the US. It added that currently more than 80 percent of the US blood supply is tested on Novartis' testing platforms, which were co-developed with molecular diagnostics firm Gen-Probe.

According to a Novartis spokesperson, the deal launches the firm into the blood genotyping market.

Novartis said in a statement that "[a]lthough the use of molecular biology tests in transfusion compatibility testing is still at its early stages, its use is expected to become more widespread as a result of hemovigilance and transfusion safety plans being introduced in many countries."

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.